Abstract Tumour necrosis factor (TNF)-a is a proinflammatory cytokine, which is synthesised and released in the brain by astrocytes, microglia and neurons in response to numerous internal and external stimuli. It is involved in many physiological and pathophysiological processes such as gene transcription, cell proliferation, apoptosis, synaptic signalling and neuroprotection. The complex actions of TNF-a in the brain are under intense investigation. TNF-a has the ability to induce selective necrosis of some cells whilst sparing others and this has led researchers to discover multiple activated signalling cascades. In many human diseases including acute stroke and inflammation and those involving hypoxia, levels of TNF-a are increased throughout different brain regions. TNF-a signalling may also have several positive and negative effects on neuronal function including glutamatergic synaptic transmission and plasticity. Exogenous TNF-a may also exacerbate the neuronal response to hypoxia. This review will summarise the actions of TNF-a in the central nervous system on synaptic signalling and its effects during hypoxia.
Introduction
Tumour necrosis factor (TNF)-a is a pro-inflammatory cytokine, which was initially described as a necrotic factor in peripheral inflammation, which induced cell death in tumour cell lines in vitro and transplanted tumours in vivo [1] . In the brain, it is synthesised and released by astrocytes [2] , microglia [3] and neurons [4, 5] . It is constitutively expressed as its non-active larger trans-membrane form (26 kDa protein), which is cleaved at its extracellular domain by TNF-a converting enzyme to produce a 17-kDa active protein, by a process known as 'ectodomain shedding' [6] . The varied and complex functions of TNF-a are currently under intense investigation. To date, TNF-a has been shown to be involved in a multiplicity of physiological processes such as cell proliferation and differentiation [7, 8] , gene transcription [9, 10] and up-regulation of neuroprotective mediators [11, 12] . It is TNF-a's ability to induce selective necrosis of some cells whilst sparing others that has led researchers to discover multiple activated signalling cascades.
There is much evidence to date that TNF-a and TNF receptor (TNFR) signalling is increased in many neurological disorders including Alzheimer's disease, Parkinson's disease, ischaemia, multiple sclerosis and traumatic brain injury [13] [14] [15] [16] [17] to name but a few. It is also now widely accepted that centrally expressed TNF-a can regulate synaptic signalling and synaptic plasticity and induce structural changes at the synaptic level [18, 19] . This review will focus on the actions of TNF-a, through its central receptors in the central nervous system, on synaptic signalling and plasticity and the effects of TNF-a during hypoxia.
TNF-a receptor expression and signal transduction in the CNS
Tumour necrosis factor-a surface receptors are found on both neuronal [20, 21] and glial cell population [22] , along with endothelial cells of the cerebral vasculature [23] . Two distinct TNF-a receptors have been identified, the low affinity TNFR1 (p55) and the high affinity TNFR2 (p75) receptor [24] . Binding of homotrimeric TNF-a to either receptor can activate three major signalling cascades [25] . First, there can be an interaction of the ligand-bound TNFR with the TNF receptor-associated death domain (TRADD), initiating the apoptotic-signalling cascade. This causes the recruitment of fas and its internalization and subsequent activation of caspase-8 [26] . Second, TNF-a can activate the nuclear factor kappa B (NFkB) signalling pathway where its translocates to the nucleus and regulates gene transcription. The activation of NFjB signalling by the TNFR can promote cell survival signal cascades. It seems that the rate and persistence of NFkB activation differ depending on receptor subtype activated, which may account for the difference in their overall response [27] . Third, TNF-a can activate the JNK signalling pathway resulting in the enhanced activity of several transcription factors such as AP-1. These signalling cascades are not mutually exclusive to the individual receptors [28] . Most cell types express both TNFR1 and TNFR2 receptors and thus the overlap in their signalling cascades adds to the complexity of the overall effect of TNF-a. Finally, it has been postulated that it is the ratio TNFR1:TNFR2 receptor expression that may govern the overall outcome of TNF-a action. Figure 1 shows a schematic cartoon of the signalling events triggered by activation of TNFR1 and TNFR2 in the brain.
TNF-a and synaptic signalling
There is now accumulated evidence that TNFR signalling is correlated with glutamatergic synaptic transmission and plasticity [29] . Long-term treatment with TNF-a was shown to enhance calcium currents and reduce N-methyl-Daspartate (NMDA)-induced currents by a mechanism involving activation of NF-jB [30] . TNFR receptor activation increases a-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor (AMPAR) trafficking to the membrane surface of neurons while decreasing GABAa receptor surface expression [31] . These TNFR signalling effects were mediated by increases in the amplitude and frequency of mEPSCs and decreases in the amplitude of mIPSCs [29, 32] (Fig. 2 ).
TNF-a and synaptic plasticity
In the early 1990s, exogenous application of TNF-a was shown to have inhibitory effects on synaptic plasticity and long-term potentiation (LTP), an electrophysiological correlate of learning and memory [37, 38] . Later it was shown that the JNK and p38 MAP kinase played an important role in this inhibitory effect on LTP [39, 40] . These mechanisms may be similar for the effects of other pro-inflammatory cytokines such as IL-1b on LTP [41, 42] . It would seem that p38 MAPK plays a role in early LTP but not late LTP [39] . The inhibitory effects of TNF on LTP were also augmented by nicotine application [43] , whilst a-methyl-4-carboxyphenylglycine (MCPG), 2-methyl-6-(phenylethynyl) pyridine (MPEP; both antagonists for the metabotropic glutamate receptor) and ryanodine, reversed the inhibitory effect of TNF-a on LTP [44] . Interestingly, knockout mice for TNFR1 show full LTP, highlighting potential differences in basal activity of TNF-a and excessive production of TNF-a [31].
Tumour necrosis factor-a signalling has also been shown to have a role in long-term depression (LTD), another electrophysiological process purported to provide insight into memory consolidation. Mice deficient for TNF-a receptors (TNFR-KO mice) display no LTD [45] . Its modulation of synaptic plasticity (LTP and LTD) is predominantly as a result of the direct neuronal-glial crosstalk. During synaptic transmission, glutamate-mediated activation of glial metabotropic glutamate receptors may stimulate the release of TNF-a into the synapse [46]. TNF-a can then diffuse and bind to its receptors found on the neuronal plasma membranes and initiate signalling cascades involved in increased synthesis and trafficking of AMPA receptors to the post synaptic density, thus enhancing synaptic efficacy [29] . Indeed, this study by Beattie, also demonstrated that by removing TNF-a-mediated signalling, using soluble TNFR1 decoy receptor, a reduction in AMPAR surface expression on hippocampal neuronal membranes occurred [29] . These findings highlight the important contribution of the inflammatory mediator to the maintenance and modulation of hippocampal excitatory synapses (a process known as synaptic scaling). Thus, under normal physiological and pathophysiological levels TNF-a plays an important role in the regulation of synaptic plasticity and in the consolidation of memory within the hippocampus [32, 39, 45].
TNF-a and hypoxia in the CNS
When faced with low blood oxygen levels, hypoxia, humans reflexly engage a number of physiological changes as well as cellular intrinsic homeostatic mechanisms [47] . To date, most research has concentrated on the cellular adaptation that requires long-tem adaptive changes including gene expression changes, which involve transcription factors [48] . Another problem associated with hypoxia is the acute and chronic occurrence of inflammation in the affected region with the release of pro-inflammatory cytokines such as TNF-a. TNF-a has been shown to interact with adenosine in its effects during hypoxia. Very little is known about this interaction [49, 50] . Hypoxia induces oxidative stress in the brain [51, 52] and is associated with increased levels of pro-inflammatory cytokines, such as TNF-a in pig [53] , in humans [54] and in mice [55] . Indeed, the levels of TNF-a may remain elevated in the affected brain tissue for at least 24 h after an ischaemic insult [16, 56] and TNF-a itself causes oxidative stress in the brain [57] .
Past studies have shown that the excess glutamate produced by excitatory amino-acid transporter (EAAT) inactivation may be a key component in the contribution of TNF-a to cerebral hypoxia and ischaemia. This excess glutamate remains in the extracellular space leading to glutamate-induced excitotoxicity due to EAAT dysfunction during ischaemia. TNF-a signalling through TNFR1, caspase and ceramide, can be neurotoxic to cells and induce apoptosis while TNF-a signalling through TNFR2 and gene transcription pathways has neuro-protective effects in neurones and glia. Most recently, it has been shown that TNF-a is neuro-protective against hypoxia-induced hyperexcitability in hippocampal neurons [58] .
Some of the first evidence showing a link between TNF-a and hypoxia inducible factor, a key regulator in the transcriptional response to hypoxia, came from the laboratory of Zhou et al. [59] where they showed that TNF-a released from activated macrophages could stabilize HIF-1a in resting tubular LLC-PK1 cells. Also Jung et al. [60] described a novel mechanism of HIF-1a up-regulation and they identified HIF-1a as a unique component of the Fig. 1 TNF-a NF-kappa B-mediated inflammatory/survival response.
More recently, Goel et al. [61] suggest that TNF-a and HSP-70 together enhance the decrease in pro-apoptotic protein levels and the increase in anti-apoptotic protein levels in the event of neuronal hypoxia through ERK1/2 signal transduction. It has also been shown that that apoptosis of cortical neurons after oxygen-glucose deprivation is mediated by TNF-a/TNF-a receptor 1 [62] . The novel cytokine, TNF-like weak inducer of apoptosis (TWEAK) may be a potential prophylactic strategy to protect the brain from the devastating effects of an ischaemic injury. Also the cytokine TWEAK and its receptor fibroblast growth factor-inducible 14 have a neuroprotective effect in the central nervous system [63] . Our laboratories have recently shown that the recovery of hippocampal neurons from 2 h hypoxia can be significantly impaired by addition of pathophysiological levels of TNF-a [64] . This effect was reversed by prior application of a p38MAPK inhibitor. A novel role for prolyl hydroxylases (which regulate HIF1-a stability in neurons) and TNF-a during hypoxia may also be emerging. Our laboratories have recently shown that synaptic plasticity in the dentate gyrus is significantly enhanced post hypoxia and in the presence of exogenous TNF-a [65, 66] . Together, all of these studies highlight the vast detrimental effects of TNFa on both glial and neuronal functioning during cerebral hypoxia and ischaemia.
Concluding remarks
It is now accepted that the role of TNF-a as a central neuro-inflammatory mediator also extends to complex physiological processes in the CNS. Its many signalling cascades give rise to multiple effects on synaptic transmission and plasticity. TNF-a also plays a major role in hypoxic and ischaemic events in the brain. Our understanding of the role of this pro-inflammatory agent in these effects will undoubtedly give rise to new therapeutic targets. 
